{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-26-000023","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2026-08-05T20:02:17+00:00","discovered_at":"2026-08-05T20:03:07.668685+00:00","generated_at":"2026-08-05T20:03:12.530080+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Black Diamond Therapeutics Q2 2026 net loss $9.9M; silevertinib shows 60% ORR in NSCLC","bullets":["Cash, equivalents, and investments $110.5M as of June 30, 2026; runway into 2H 2028.","Net loss $9.9M vs $10.6M in Q2 2025; R&D expenses $7.4M, G&A $4.7M.","Phase 2 silevertinib in frontline non-classical EGFRm NSCLC: ORR 60%, CNS ORR 86%, median PFS 15.2 months.","No patients developed de novo brain metastases; 53% remain on therapy, longest 23.5 months.","FDA feedback on pivotal path for silevertinib in frontline NSCLC expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-26-000023","json":"https://secwatch.observer/filing/0001701541-26-000023.json","markdown":"https://secwatch.observer/filing/0001701541-26-000023.md","text":"https://secwatch.observer/filing/0001701541-26-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154126000023/0001701541-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154126000023/bdtx-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:03:12.530080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}